242614 ⎘
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
#2Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
#3Modulators of ATP-binding cassette transporters
#4Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
#5DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
#6Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
#7Use of glucosidase inhibitors for therapy of mucovisidosis
#8Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
#9Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
#10METHODS AND UNIT DOSE FORMULATIONS FOR THE INHALATION ADMINISTRATION OF AMINOGLYCOSIDE ANTIBIOTICS
#11Compositions and methods for therapy for diseases characterized by defective chloride transport
#12METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS
#13Di(uridine 5′-)tetraphosphate and salts thereof
#14P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
#15Propellant-based nanoparticulate dry powder aerosols and method of making
#16Methods and Compositions For P2X Receptor Calcium Entry Channels and Other Calcium Entry Mechanisms
#17Method of treating neutrophil-related diseases with topical anesthetics
#18Treatment of respiratory diseases
#19Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
#20Modulators of ATP-binding cassette transporters
#21Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
#22Use of glucosidase inhibitors for therapy of mucovisidosis
#23P-(2′-deoxycytidine 5′-)P-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis
#24Treating pulmonary disorders with gaseous agent causing repletion of GSNO
#25Di(uridine 5′-)tetraphosphate and salts thereof
#26Treatment of mucosal membranes
#27Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
#28Methods and compositions for P2X receptor calcium entry channels and other calcium entry mechanisms
#29Method of treating neutrophil-related diseases with topical anesthetics
#30Therapeutic treatments using the direct application of antimicrobial metal compositions
#31Treatment of inflammatory skin conditions
#32Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
#33Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
#34Di(uridine 5′-)tetraphosphate and salts thereof
#35Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
#36Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
#37Anti-asthmatic combinations comprising surface active phospholipids
#38Methods for encapsulating plasmids in lipid bilayers
#39Treatment of respiratory diseases